Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung08: datopotamab deruxtecan plus pembrolizumab versus pembrolizumab in first-line PD-L1-high advanced or metastatic NSCLC without driver alterations
CTR20220788Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Nov 2022; status: active.
02
Drugs
datopotamab deruxtecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220788.